

Drug Policy:

Istodax™ (romidepsin)

POLICY NUMBER UM ONC_1230	SUBJECT Istodax™ (romidepsin)		DEPT/PROGRAM UM Dept	PAGE 1 OF 2
DATES COMMITTEE REVIEWED 12/12/12, 12/11/13, 03/11/15, 03/27/15, 05/24/16, 03/07/17, 03/14/18, 03/07/19, 12/11/19, 03/11/20, 01/13/21, 08/11/21	APPROVAL DATE August 11, 2021	EFFECTIVE DATE August 27, 2021	COMMITTEE APPROVAL DATES 12/12/12, 12/11/13, 03/11/15, 03/27/15, 05/24/16, 03/07/17, 03/14/18, 03/07/19, 12/11/19, 03/11/20, 01/13/21, 08/11/21	
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Utilization Management Committee		
URAC STANDARDS HUM 1	NCQA STANDARDS UM 2		ADDITIONAL AREAS OF IMPACT	
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS		APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

I. PURPOSE

To define and describe the accepted indications for Istodax (romidepsin) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)
2. When health plan Exchange coverage provisions-including any applicable PDLs (Preferred Drug Lists)-conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)

3. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the [Preferred Drug Guidelines](#) shall follow [NCH L1 Pathways](#) when applicable, otherwise shall follow NCH drug policies **AND**
4. Continuation requests of previously approved, non-preferred medication are not subject to this provision **AND**
5. When available, generic alternatives are preferred over brand-name drugs.

B. Cutaneous T-Cell Lymphomas (CTCL)

1. The member has relapsed/refractory CTCL (including mycosis fungoides or Sezary syndrome) **AND**
2. Istodax (romidepsin) is being used as a single agent **AND**
3. The member has experienced disease progression on one prior systemic therapy.

III. EXCLUSION CRITERIA

- A. Disease progression while taking Istodax (romidepsin) or another histone deacetylase inhibitor (i.e. vorinostat).
- B. Concurrent use with other chemotherapy.
- C. Dosing exceeds single dose limit of Istodax (romidepsin) 14mg/m².
- D. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

- A. None

VII. REFERENCES

- A. Istodax prescribing information. Celgene Corporation. Summit, NJ 2021.
- B. Clinical Pharmacology Elsevier Gold Standard 2021.
- C. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, CO 2021.
- D. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2021.
- E. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2021.